Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biogen Idec
Tysabri shows significant reduction in steroid use, hospitalizations in multiple sclerosis
November 7th, 2006
Biogen Idec (BIIB) and Elan Corporation (ELN) announced data on Phase III studies that show Tysabri (natalizumab) therapy significantly reduced corticosteroid use and hospitalizations, and increased the proportion of MS patients with no disease activity. The AFFIRM monotherapy study (two-year, randomized, multicenter, placebo-controlled, double-blind study of 942 patients conducted in 99 sites worldwide), showed the impact of Tysabri on two prespecified endpoints, the annualized rate of relapses requiring corticosteroid use and the annualized rate of hospitalizations due to MS. Data showed a 69% relative reduction in the annualized rate of relapses...
Source: Drug Law Weekly (2006-11-07)
|
